par Jeschke, Jana 
;Bizet, Martin ;Desmedt, Christine ;Calonne, Emilie ;Dedeurwaerder, Sarah ;Garaud, Soizic ;Koch, Alexander;Larsimont, Denis ;Salgado, Roberto;Van den Eynden, Gert;Willard-Gallo, Karen ;Bontempi, Gianluca ;Defrance, Matthieu ;Sotiriou, Christos ;Fuks, François
Référence The Journal of clinical investigation, 127, 8, page (3090-3102)
Publication Publié, 2017-08
;Bizet, Martin ;Desmedt, Christine ;Calonne, Emilie ;Dedeurwaerder, Sarah ;Garaud, Soizic ;Koch, Alexander;Larsimont, Denis ;Salgado, Roberto;Van den Eynden, Gert;Willard-Gallo, Karen ;Bontempi, Gianluca ;Defrance, Matthieu ;Sotiriou, Christos ;Fuks, François Référence The Journal of clinical investigation, 127, 8, page (3090-3102)
Publication Publié, 2017-08
Article révisé par les pairs
| Résumé : | The tumor immune response is increasingly associated with better clinical outcomes in breast and other cancers. However, the evaluation of tumor-infiltrating lymphocytes (TILs) relies on histopathological measurements with limited accuracy and reproducibility. Here, we profiled DNA methylation markers to identify a methylation of TIL (MeTIL) signature that recapitulates TIL evaluations and their prognostic value for long-term outcomes in breast cancer (BC). |
